| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1581280/0001214659-26-004893.txt","as_of":"2026-04-22T03:03:32.063787+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1581280/0001214659-26-004893.txt","company":"Twist Bioscience Corp","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1581280/0001214659-26-004893.txt","article_chars":1631,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_4d6027d91fff00ff","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1581280/0001214659-26-004893.txt","content_type":"text/plain","enriched_at":"2026-04-22T03:17:06.032224+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1581280/0001214659-26-004893.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1581280/0001214659-26-004893.txt","source_event_id":"evt_aebdbfa8a03d","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"93922d193462e56c","kind":"sec_filing","published_at":"20260421","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-17","2026-04-21","2025-05-08"],"entities":[{"asset_class":"equity","name":"Twist Bioscience Corp","relevance":"high","symbol":"TWST","type":"issuer"},{"asset_class":"equity","name":"Adam Laponis","relevance":"high","symbol":"","type":"reporting_person"},{"asset_class":"equity","name":"Kendra Fox","relevance":"low","symbol":"","type":"attorney_in_fact"}],"event_type":"listing","information_gaps":["The cleaned text does not include the specific transaction details (e.g., number of shares, price, whether it was a buy/sell, and any remaining holdings).","The signal headline says \u201cTWST filed 4,\u201d but the exact change vs prior known state is not provided in the supplied text (no prior filing comparison data included).","No explicit description of the transaction type (purchase/sale) is present in the provided excerpt beyond the Rule 10b5-1 statement."],"key_facts":["SEC filing is Form 4 (SEC Act: 1934 Act; SEC file number 001-38720).","Issuer: Twist Bioscience Corp (TWST).","Reporting person: Adam Laponis, identified as Chief Financial Officer.","Conformed period of report: 20260417.","Filed as of date: 20260421.","The transaction is stated to be effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person on May 8, 2025.","The filing includes a signature: /s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis, dated 2026-04-21."],"numeric_claims":[{"label":"Rule 10b5-1 plan adoption date","value":"2025-05-08"},{"label":"Conformed period of report","value":"2026-04-17"},{"label":"Filed as of date","value":"2026-04-21"}],"primary_claim":"The Form 4 filed on 2026-04-21 reports a common stock transaction by Adam Laponis, effected under a Rule 10b5-1 trading plan adopted May 8, 2025.","relevance_score":0.55,"sentiment":"neutral","source_quality":"medium","summary":"Twist Bioscience Corp (TWST) filed a Form 4 on 2026-04-21 reporting a transaction by Adam Laponis (CFO) for common stock, dated for the reporting period 2026-04-17. The filing states the trade was executed under a Rule 10b5-1 trading plan adopted on May 8, 2025.","topics":["SEC Form 4","insider trading","Rule 10b5-1 trading plan","common stock transaction","Twist Bioscience Corp"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Twist Bioscience Corp \u00b7 Filed 20260421","ticker":"TWST","tickers":["TWST"],"title":"TWST filed 4","url":"https://www.sec.gov/Archives/edgar/data/1581280/0001214659-26-004893.txt"}... |